Amundi Sells 22,140 Shares of LivaNova PLC (NASDAQ:LIVN)

Amundi decreased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 183,293 shares of the company's stock after selling 22,140 shares during the quarter. Amundi owned 0.34% of LivaNova worth $8,805,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Atria Investments Inc increased its stake in LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company's stock worth $297,000 after acquiring an additional 331 shares during the period. Central Pacific Bank Trust Division increased its position in shares of LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after purchasing an additional 720 shares during the period. Amalgamated Bank raised its stake in LivaNova by 3.0% in the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company's stock valued at $1,153,000 after purchasing an additional 729 shares in the last quarter. Rhumbline Advisers grew its stake in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after buying an additional 899 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after buying an additional 1,424 shares during the period. Institutional investors own 97.64% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have commented on LIVN shares. Mizuho lowered their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Barclays lowered their price target on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. The Goldman Sachs Group decreased their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus decreased their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $61.17.

LivaNova Trading Down 2.4 %

Shares of LivaNova stock traded down $1.00 on Tuesday, hitting $40.41. The stock had a trading volume of 642,560 shares, compared to its average volume of 600,741. The stock has a 50 day moving average of $45.88 and a 200 day moving average of $49.01. The firm has a market capitalization of $2.20 billion, a P/E ratio of 96.21 and a beta of 1.10. LivaNova PLC has a twelve month low of $36.85 and a twelve month high of $64.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.